ADVANCING THE STANDARD
OF CARE IN OPHTHALMICS
Visiox is a privately funded biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options. Each day is an opportunity for us to disrupt and revolutionize the current market to maximize patient and physician satisfaction. As an agile business partner, we will achieve this through a high level of collaboration with all eye care professionals.
Our lead asset, Omlonti® (omidenepag isopropyl ophthalmic solution) 0.002%, is an EP2 receptor agonist for ocular hypertension and open-angle glaucoma. It received FDA approval in September 2022.
Our next asset, PDP-716, is a once-daily brimonidine for ocular hypertension and open angle glaucoma. The NDA submission was accepted with a PDUFA target action date of August 4, 2023.
Our third asset, SDN-037, is a twice daily topical difluprednate for post-surgical inflammation and pain. Each product utilizes a unique, proprietary, extended release technology that is patent protected through at least 2036.
PDP-716, SDN-037, and TearActTM delivery technology were licensed by Visiox from Sun Pharma Advanced Research Company Ltd.
(omidenepag isopropyl ophthalmic solution) 0.002%
EP2 receptor agonist with a new mechanism of action for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Once-daily brimonidine for ocular hypertension and open angle glaucoma utilizing our patented TearAct™ fine resin technology.
Twice daily topical difluprednate for post-surgical inflammation and pain utilizing our patented TJM micellar platform.
Visiox is leading the development and commercialization of best-in-class formulations of well-known compounds treating highly prevalent conditions of the eye. Our two lead assets are preparing for launch, and we are aggressively building our portfolio.